Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

HIV RNA, CD4+ Percentage, and Risk of Hepatocellular Carcinoma by Cirrhosis Status.

Torgersen J, Kallan MJ, Carbonari DM, Park LS, Mehta RL, D'Addeo K, Tate JP, Lim JK, Goetz MB, Rodriguez-Barradas MC, Gibert CL, Bräu N, Brown ST, Roy JA, Taddei TH, Justice AC, Re VL.

J Natl Cancer Inst. 2019 Nov 5. pii: djz214. doi: 10.1093/jnci/djz214. [Epub ahead of print]

PMID:
31687755
2.

Differences in Pathology, Staging, and Treatment between HIV+ and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma.

Torgersen J, Taddei TH, Park LS, Carbonari DM, Kallan MJ, Mitchell Richards K, Zhang X, Jhala D, Bräu N, Homer R, D'Addeo K, Mehta R, Skanderson M, Kidwai-Khan F, Justice AC, Lo Re V  III.

Cancer Epidemiol Biomarkers Prev. 2019 Oct 1. doi: 10.1158/1055-9965.EPI-19-0503. [Epub ahead of print]

PMID:
31575557
3.

Concordance of hospitalizations between Clinical Practice Research Datalink and linked Hospital Episode Statistics among patients treated with oral antidiabetic therapies.

Saine ME, Carbonari DM, Newcomb CW, Gallagher AM, Blak BT, Roy JA, Wood J, Cardillo S, Hennessy S, Strom BL, Lo Re V 3rd.

Pharmacoepidemiol Drug Saf. 2019 Oct;28(10):1328-1335. doi: 10.1002/pds.4853. Epub 2019 Jul 22.

PMID:
31328342
4.

Determinants of Liver Complications Among HIV/Hepatitis B Virus-Coinfected Patients.

Lo Re V 3rd, Newcomb CW, Carbonari DM, Roy JA, Althoff KN, Kitahata MM, Reddy KR, Lim JK, Silverberg MJ, Mayor AM, Horberg MA, Cachay ER, Kirk GD, Hull M, Gill J, Sterling TR, Kostman JR, Peters MG, Moore RD, Klein MB, Kim HN; North American AIDS Cohort Collaboration on Research and Design of IeDEA.

J Acquir Immune Defic Syndr. 2019 Sep 1;82(1):71-80. doi: 10.1097/QAI.0000000000002094.

PMID:
31107304
5.

Absolute Insurer Denial of Direct-Acting Antiviral Therapy for Hepatitis C: A National Specialty Pharmacy Cohort Study.

Gowda C, Lott S, Grigorian M, Carbonari DM, Saine ME, Trooskin S, Roy JA, Kostman JR, Urick P, Lo Re V 3rd.

Open Forum Infect Dis. 2018 Jun 7;5(6):ofy076. doi: 10.1093/ofid/ofy076. eCollection 2018 Jun.

6.

Validity of diagnostic codes to identify hospitalizations for infections among patients treated with oral anti-diabetic drugs.

Saine ME, Gizaw M, Carbonari DM, Newcomb CW, Roy JA, Cardillo S, Esposito DB, Bhullar H, Gallagher AM, Strom BL, Lo Re V 3rd.

Pharmacoepidemiol Drug Saf. 2018 Oct;27(10):1147-1150. doi: 10.1002/pds.4368. Epub 2017 Dec 18.

PMID:
29250905
7.

Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes.

Lo Re V, Carbonari DM, Saine ME, Newcomb CW, Roy JA, Liu Q, Wu Q, Cardillo S, Haynes K, Kimmel SE, Reese PP, Margolis DJ, Apter AJ, Reddy KR, Hennessy S, Bhullar H, Gallagher AM, Esposito DB, Strom BL.

BMJ Open Diabetes Res Care. 2017 Jul 31;5(1):e000400. doi: 10.1136/bmjdrc-2017-000400. eCollection 2017.

8.

The Reply.

Lo Re V 3rd, Carbonari DM, Lewis JD, Roy JA, Corley DA.

Am J Med. 2017 Aug;130(8):e369. doi: 10.1016/j.amjmed.2017.03.062. No abstract available.

PMID:
28734384
9.

Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection.

Lo Re V Rd, Zeldow B, Kallan MJ, Tate JP, Carbonari DM, Hennessy S, Kostman JR, Lim JK, Goetz MB, Gross R, Justice AC, Roy JA.

Pharmacoepidemiol Drug Saf. 2017 Oct;26(10):1172-1181. doi: 10.1002/pds.4258. Epub 2017 Jul 19.

10.

Risk of Acute Liver Injury With Antiretroviral Therapy by Viral Hepatitis Status.

Gowda C, Newcomb CW, Liu Q, Carbonari DM, Lewis JD, Forde KA, Goldberg DS, Reddy KR, Roy JA, Marks AR, Schneider JL, Kostman JR, Tate JP, Lim JK, Justice AC, Goetz MB, Corley DA, Lo Re V.

Open Forum Infect Dis. 2017 Jan 28;4(2):ofx012. doi: 10.1093/ofid/ofx012. eCollection 2017 Spring.

11.

Evaluation of methods to estimate missing days' supply within pharmacy data of the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN).

Lum KJ, Newcomb CW, Roy JA, Carbonari DM, Saine ME, Cardillo S, Bhullar H, Gallagher AM, Lo Re V 3rd.

Eur J Clin Pharmacol. 2017 Jan;73(1):115-123. doi: 10.1007/s00228-016-2148-4. Epub 2016 Oct 27.

PMID:
27787616
12.

Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance.

Lo Re V 3rd, Gowda C, Urick PN, Halladay JT, Binkley A, Carbonari DM, Battista K, Peleckis C, Gilmore J, Roy JA, Doshi JA, Reese PP, Reddy KR, Kostman JR.

Clin Gastroenterol Hepatol. 2016 Jul;14(7):1035-43. doi: 10.1016/j.cgh.2016.03.040. Epub 2016 Apr 5.

13.

Reply.

Lo Re V 3rd, Forde KA, Lewis JD, Goldberg DS, Carbonari DM, Roy J, Reddy KR, Sha D, Strom BL, Corley DA.

Clin Gastroenterol Hepatol. 2016 Jun;14(6):918-919. doi: 10.1016/j.cgh.2016.02.013. Epub 2016 Feb 15. No abstract available.

PMID:
26883072
14.

Oral Azole Antifungal Medications and Risk of Acute Liver Injury, Overall and by Chronic Liver Disease Status.

Lo Re V 3rd, Carbonari DM, Lewis JD, Forde KA, Goldberg DS, Reddy KR, Haynes K, Roy JA, Sha D, Marks AR, Schneider JL, Strom BL, Corley DA.

Am J Med. 2016 Mar;129(3):283-91.e5. doi: 10.1016/j.amjmed.2015.10.029. Epub 2015 Nov 17.

15.

Use of demographic and pharmacy data to identify patients included within both the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN).

Carbonari DM, Saine ME, Newcomb CW, Blak B, Roy JA, Haynes K, Wood J, Gallagher AM, Bhullar H, Cardillo S, Hennessy S, Strom BL, Lo Re V 3rd.

Pharmacoepidemiol Drug Saf. 2015 Sep;24(9):999-1003. doi: 10.1002/pds.3844. Epub 2015 Jul 27.

PMID:
26213344
16.

Risk of Acute Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy's Law and a New Prognostic Model.

Lo Re V 3rd, Haynes K, Forde KA, Goldberg DS, Lewis JD, Carbonari DM, Leidl KB, Reddy KR, Nezamzadeh MS, Roy J, Sha D, Marks AR, De Boer J, Schneider JL, Strom BL, Corley DA.

Clin Gastroenterol Hepatol. 2015 Dec;13(13):2360-8. doi: 10.1016/j.cgh.2015.06.020. Epub 2015 Jun 27.

17.

Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs.

Saine ME, Carbonari DM, Newcomb CW, Nezamzadeh MS, Haynes K, Roy JA, Cardillo S, Hennessy S, Holick CN, Esposito DB, Gallagher AM, Bhullar H, Strom BL, Lo Re V 3rd.

BMC Pharmacol Toxicol. 2015 Apr 2;16:8. doi: 10.1186/s40360-015-0007-z.

18.

Validity of diagnostic codes and laboratory tests of liver dysfunction to identify acute liver failure events.

Lo Re V 3rd, Carbonari DM, Forde KA, Goldberg D, Lewis JD, Haynes K, Leidl KB, Reddy RK, Roy J, Sha D, Marks AR, Schneider JL, Strom BL, Corley DA.

Pharmacoepidemiol Drug Saf. 2015 Jul;24(7):676-83. doi: 10.1002/pds.3774. Epub 2015 Apr 10.

19.

Increased risk of hip fracture associated with dually treated HIV/hepatitis B virus coinfection.

Byrne DD, Newcomb CW, Carbonari DM, Nezamzadeh MS, Leidl KB, Herlim M, Yang YX, Hennessy S, Kostman JR, Leonard MB, Localio AR, Lo Re V 3rd.

J Viral Hepat. 2015 Nov;22(11):936-47. doi: 10.1111/jvh.12398. Epub 2015 Mar 6.

20.

Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated health care system.

Goldberg DS, Forde KA, Carbonari DM, Lewis JD, Leidl KB, Reddy KR, Haynes K, Roy J, Sha D, Marks AR, Schneider JL, Strom BL, Corley DA, Lo Re V 3rd.

Gastroenterology. 2015 Jun;148(7):1353-61.e3. doi: 10.1053/j.gastro.2015.02.050. Epub 2015 Feb 28.

21.

Risk of hip fracture associated with untreated and treated chronic hepatitis B virus infection.

Byrne DD, Newcomb CW, Carbonari DM, Nezamzadeh MS, Leidl KB, Herlim M, Yang YX, Hennessy S, Kostman JR, Leonard MB, Localio AR, Lo Re V 3rd.

J Hepatol. 2014 Aug;61(2):210-8. doi: 10.1016/j.jhep.2014.04.001. Epub 2014 Apr 5.

22.

Prevalence of diagnosed chronic hepatitis B infection among U.S. Medicaid enrollees, 2000-2007.

Byrne DD, Newcomb CW, Carbonari DM, Nezamzadeh MS, Leidl KB, Herlim M, Yang YX, Hennessy S, Kostman JR, Leonard MB, Localio R, Lo Re V 3rd.

Ann Epidemiol. 2014 Jun;24(6):418-23. doi: 10.1016/j.annepidem.2014.02.013. Epub 2014 Mar 5.

23.

Validity of diagnostic codes to identify cases of severe acute liver injury in the US Food and Drug Administration's Mini-Sentinel Distributed Database.

Lo Re V 3rd, Haynes K, Goldberg D, Forde KA, Carbonari DM, Leidl KB, Hennessy S, Reddy KR, Pawloski PA, Daniel GW, Cheetham TC, Iyer A, Coughlin KO, Toh S, Boudreau DM, Selvam N, Cooper WO, Selvan MS, VanWormer JJ, Avigan MI, Houstoun M, Zornberg GL, Racoosin JA, Shoaibi A.

Pharmacoepidemiol Drug Saf. 2013 Aug;22(8):861-72. doi: 10.1002/pds.3470. Epub 2013 Jun 25.

24.

Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies.

Lo Re V 3rd, Haynes K, Ming EE, Wood Ives J, Horne LN, Fortier K, Carbonari DM, Hennessy S, Cardillo S, Reese PP, Reddy KR, Margolis D, Apter A, Kimmel SE, Roy J, Freeman CP, Razzaghi H, Holick CN, Esposito DB, Van Staa TP, Bhullar H, Strom BL.

Pharmacoepidemiol Drug Saf. 2012 Nov;21(11):1202-15. doi: 10.1002/pds.3318. Epub 2012 Jul 5.

PMID:
22763953
25.

Behavioral, structural and molecular changes following long-term hippocampal IL-1β overexpression in transgenic mice.

Hein AM, Zarcone TJ, Parfitt DB, Matousek SB, Carbonari DM, Olschowka JA, O'Banion MK.

J Neuroimmune Pharmacol. 2012 Mar;7(1):145-55. doi: 10.1007/s11481-011-9294-3. Epub 2011 Jul 12.

Supplemental Content

Loading ...
Support Center